Achieve Life Sciences stock
ACHVNASDAQAchieve Life Sciences, Inc., HealthcareISIN US0044685008
41Score 41 out of 100, Weak
Price and trend
78 / 100
Price history
+48% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 21% below its 52-week high. Largest decline in 20 years: 100% (June 2007 to April 2025).
Chart figures for advanced users
- SMA 50$7.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.67
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.65
- The lowest closing price of the last twelve months.
- Resistance$8.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Achieve Life Sciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $697.68M, is number 215 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 41 out of 100 (Weak): rank 515 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $201.52M, financial debt $14.05M.Stability 53
Weaknesses
- DilutionShare count up 437% since 2021.Capital allocation 18
- Loss-makingLoss of $111.71M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$44.1M over the last 12 months.Fundamentals 17
Its standout strengths are technical analysis and momentum, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 10 Nov 2026EPS reported −$0.11 (expected −$0.20)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.460.0%
- Revenue
- $4.5M0.0%
- Earnings per share
- −$0.680.0%
- Revenue
- $35.42M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +6.6%The company expects to receive a complete response letter from the FDA on or by the June 20 date, and now expects a commercial launch in the first half of 2027.
“In mid-April, the company announced it expects to receive a complete response letter from the FDA on or by our June 20 PDUFA date due to a separate third-party manufacturer having received an official action indicated classification.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Achieve Life Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Attovia TherapeuticsATTO $722.72M44
- OmniAbOABI $722.01M54
- Prime MedicinePRME $705.56M37
- Janux TherapeuticsJANX $703.61M33
- Nuvectis PharmaNVCT $695.69M46
- Ginkgo Bioworks HoldingsDNA $688.89M41
- Kura OncologyKURA $682.66M27
- Design TherapeuticsDSGN $677.5M37
ETFs that hold Achieve Life Sciences
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 9 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2009)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.